Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
April 2014 Vol 7, No 2
Clinical
Infliximab Dosing Patterns in a Sample of Patients with Crohn’s Disease: Results from a Medical Chart Review
Joseph Tkacz, MS
,
Jennifer H. Lofland, PharmD, MPH, PhD
,
Julie Vanderpoel, PharmD, MPA
,
Charles Ruetsch, PhD
Stakeholder Perspective
Infliximab Dosing for Crohn’s Disease: Too Much of a Good Thing?
by
Atheer A. Kaddis, PharmD
Read More
Business
Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend
Christopher M. Blanchette, PhD, MBA
,
Nicholas J. Gross, MD, PhD
,
Pablo Altman, MD, MBA
,
F. Randy Vogenberg, PhD, FASHP
Stakeholder Perspective
Chronic Obstructive Pulmonary Disease Remains a Growing Population Health Concern
Read More
Editorial
Harnessing the Power of Big Data in Healthcare
David B. Nash, MD, MBA
Read More
Clinical
Considering Patient Preferences When Selecting Anti–Tumor Necrosis Factor Therapeutic Options
Andrea DeVries, PhD
,
Jinan Liu, PhD
,
Alexander P. Ruggieri, MD, MHS
,
Judith J. Stephenson, SM
,
Gosia Sylwestrzak, MA
Stakeholder Perspective
In a Fix on Addressing Alternatives
by
Albert Tzeel, MD, MHSA, CPE, FAAPL
Read More
Results 1 - 4 of 4